Pulmicort Turbohaler

Quick links

Choose a section

Quick links to important sections

Advertisements

Pulmicort Turbohaler

Selected form

Advertisements

Overview of Pulmicort Turbohaler

Property Description
Active ingredient Budesonide
Form Dry Powder Inhaler (DPI) (Turbohaler system)
Pharmacological class Glucocorticosteroid (Inhaled Corticosteroid)
General purpose Maintenance therapy and long-term control
Origin Synthetic

The pharmaceutical preparation Pulmicort Turbohaler is a prescription-only medication distinguished by its proprietary Turbohaler delivery system, which contains the active ingredient Budesonide. This compound is a synthetic glucocorticosteroid, a class of corticosteroid that is clinically recognized for its potent anti-inflammatory agent properties specifically within the respiratory tract.

Composition and Delivery: What is the Turbohaler Dry Powder Form?

The medication is supplied as a Dry Powder Inhaler (DPI), making it one of the established inhaled forms of Budesonide. The Turbohaler is engineered to deliver a precise dose of the finely milled, micronized Budesonide powder directly through oral inhalation. Local delivery of this single-component dry powder is intended to maximize the therapeutic presence in the airways while minimizing systemic exposure.

General Purpose: Is Pulmicort Turbohaler for Maintenance or Quick Relief?

The general purpose of this drug is strictly defined as maintenance therapy for the long-term control of chronic inflammatory respiratory issues. Its primary role is prophylactic; the sustained action of Budesonide stabilizes the inflamed airway tissue and reduces airway hyperresponsiveness over time. It is crucial to note that this medicine does not offer rapid relief, but instead works consistently to support the airways.

Regulatory References

  1. Budesonide - NIH
Advertisements

What side effects are possible with Pulmicort Turbohaler?

Possible side effects and safety information

The safety profile of Budesonide, the active ingredient in Pulmicort Turbohaler, is established in regulatory documents, classifying potential adverse reactions by their frequency and the body system affected.

Official Frequency Classification

Side effects are primarily local and are categorized based on regulatory frequency frameworks:

  • Common (may affect up to 1 in 10 people): Oral candidiasis (thrush), hoarseness (dysphonia), and throat irritation are frequently documented. Pneumonia has been reported as common, particularly in patients with Chronic Obstructive Pulmonary Disease (COPD).
  • Uncommon (may affect up to 1 in 100 people): Documented effects include anxiety, depression, tremor, muscle cramps, and cataract or blurred vision.
  • Rare (may affect up to 1 in 1,000 people): Includes signs of systemic corticosteroid effects, such as adrenal suppression, and hypersensitivity reactions like angioedema (swelling) or anaphylactic reaction.

Serious and Systemic Safety Considerations

Official labeling addresses rare but clinically important risks. Paradoxical bronchospasm, an acute tightening of the airways, is a documented serious adverse reaction that may occur immediately following inhalation. The risk of serious systemic corticosteroid effects, including Cushing’s syndrome or glaucoma, is associated with prolonged use, particularly at higher doses.

Population-Specific Notes

For the pediatric population, official documents specify the need for growth monitoring due to the risk of growth retardation with inhaled corticosteroids. Furthermore, use is generally cautioned in patients with untreated fungal or viral infections in the respiratory tract or those with known active pulmonary tuberculosis.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile indicates that an acute overdosage (a single, massive dose) of Pulmicort Turbohaler is generally not expected to be a clinical problem and no specific antidote is available. The primary concern is the risk associated with prolonged or excessive administration of the inhaled glucocorticosteroid (budesonide).

Documented Manifestations and Serious Outcomes

Long-term use at very high doses may lead to signs of systemic corticosteroid effects, primarily affecting the Hypothalamic-Pituitary-Adrenal (HPA) axis. These effects may include:

  • Hypercorticism: Signs such as Cushingoid features.
  • Adrenal Suppression: A reduction of plasma cortisol levels and, if severe, symptoms of insufficient glucocorticosteroid effect, such as tiredness, headache, nausea, and vomiting.

For children and adolescents, a documented risk of prolonged high-dose administration is potential growth retardation.

Required Emergency Actions

Situation Mandated Action (Regulatory Phrasing)
Any suspected overdose Contact a health care practitioner, hospital emergency department, or regional Poison Control Centre immediately, even if there are no symptoms.
Life-threatening symptoms Call emergency services immediately if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management of chronic overdose resulting in adrenal insufficiency involves monitoring HPA axis functions and may require a temporary increase in oral glucocorticosteroids.

Advertisements

Therapeutic Uses of Pulmicort Turbohaler

Main Uses of Pulmicort Turbohaler

Pulmicort Turbohaler is primarily used for the long-term management and maintenance treatment of bronchial asthma. It belongs to a group of medicines known as corticosteroids, which work by reducing and preventing inflammation in the airways of the lungs.

Asthma Management

As a maintenance treatment, it is used regularly to help prevent asthma attacks and reduce the frequency and severity of symptoms. It is specifically indicated for patients who require consistent treatment with anti-inflammatory medication to keep their asthma under control. This includes individuals whose symptoms are not adequately managed by occasional use of rescue inhalers.

Chronic Obstructive Pulmonary Disease (COPD)

In certain clinical contexts, this medication may also be used to treat symptomatic chronic obstructive pulmonary disease (COPD). It helps manage the persistent respiratory symptoms and reduces the frequency of exacerbations in patients with a history of repeated flare-ups.


Benefits of Treatment

The primary benefit of using Pulmicort Turbohaler is the gradual improvement of lung function and the reduction of airway sensitivity. By treating the underlying inflammation rather than just the immediate symptoms, it provides several therapeutic advantages:

  • Reduction in Symptoms: Regular use helps decrease common asthma symptoms such as shortness of breath, wheezing, and coughing.
  • Prevention of Exacerbations: It lowers the risk of severe asthma attacks and reduces the likelihood of hospitalizations related to respiratory distress.
  • Improved Quality of Life: By maintaining clearer airways over time, patients often experience better exercise tolerance and fewer disruptions to sleep and daily activities.
  • Localized Action: The medication is delivered directly to the lungs, allowing for effective treatment with lower systemic exposure compared to oral corticosteroids.
Advertisements

Eligibility and Restrictions for Use

Pulmicort Turbohaler eligibility is defined by official regulatory documentation based on age, specific clinical states, and certain comorbidities. This medicine is strictly intended for maintenance treatment and is not for immediate use in an emergency.

Eligibility and Exclusion Summary

Classification Population or Condition Status
Approved Age Group Adults, adolescents, and children aged 6 years and older Permitted for use
Use Not Established Children younger than 6 years of age Not recommended
Absolute Contraindication Acute episodes of asthma or status asthmaticus Prohibited
Hypersensitivity Known allergy to budesonide or any other ingredient Prohibited

Eligibility is further restricted for patients with specific health issues. Individuals with impaired liver function (hepatic impairment) require close monitoring, as do patients with existing infections such as tuberculosis. Use during pregnancy and lactation is conditional, requiring a physician to weigh the potential benefits against the risks.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Pulmicort Turbohaler (budesonide) is primarily metabolized in the liver by the enzyme cytochrome P450 3A4 (CYP3A4). This means that other medicines which block or inhibit this enzyme can increase the concentration of budesonide in the body. An increase in budesonide exposure may raise the potential for systemic side effects associated with corticosteroids, such as signs of Cushing’s syndrome or suppression of adrenal function.

Patients should use caution when combining this inhaled medicine with strong inhibitors of CYP3A4. Specific medicines cited in regulatory documents that have demonstrated this interaction include potent antifungal agents like ketoconazole and itraconazole, as well as the antiviral medication ritonavir. Concurrent use with such inhibitors should be approached with careful consideration, and in some cases, a dose reduction of the inhaled corticosteroid may be deemed necessary by a healthcare provider.

Similarly, substances that significantly increase the activity of the CYP3A4 enzyme may decrease the effectiveness of budesonide. Patients should fully inform their healthcare team of all prescription, over-the-counter, and herbal products currently being used. The clinical relevance of all potential interactions must be evaluated on an individual basis.

Advertisements

Mechanism of Action

How Pulmicort Turbohaler Works

The active ingredient, budesonide, functions as an agonist for the Glucocorticoid Receptor (GR), a nuclear receptor found inside target cells within the bronchial airways. Upon binding, the budesonide-GR complex translocates to the cell nucleus. The complex alters the cell's genetic output by engaging in genomic action.

This modulation involves the transrepression of genes encoding pro-inflammatory proteins (such as cytokines and chemokines) and the simultaneous transactivation of genes encoding anti-inflammatory mediators. This cascade influences the activity of multiple inflammatory cell types, including eosinophils and macrophages, by inhibiting their function and promoting their programmed cellular decline.

The resulting physiological change involves the regulation of fluid balance within the airway mucosa and modulation of responsiveness within the bronchial smooth muscle pathways. This process shifts the airway environment toward a less reactive state by altering fundamental cellular and molecular signaling.

Advertisements

Dosage and Administration Information

How Pulmicort Turbohaler is Used: Official Administration Guidelines

Pulmicort Turbohaler is designated as a maintenance therapy for long-term control, delivered exclusively via oral inhalation through the proprietary Dry Powder Inhaler (DPI) system. This medication is not intended for the immediate relief of acute or sudden breathing difficulties.

Labeled Dosing and Scheduling

Administration is typically recommended twice daily, once in the morning and once in the evening. In some patients with well-controlled asthma, once-daily evening dosing may be considered for maintenance, provided the total daily dose is within certain limits.

Usage Parameter Official Labeled Instruction
Route of Administration Oral Inhalation only
Adult Daily Range Generally 200 mu g to 1600 mu g in divided doses
Pediatric Use (ge 6 years) Specific lower daily maximums apply (e.g., le 800 mu g daily)

Procedural and Post-Use Requirements

Proper use of the Turbohaler device requires adherence to specific procedural steps. Users must load the dose by twisting the grip before placing the mouthpiece between the lips and initiating a forceful and deep inhalation.

A required step following each use is that the patient must rinse the mouth thoroughly with water and spit it out without swallowing. The dose must not be stopped abruptly; it should be titrated downwards to the lowest effective dose for long-term control once symptoms are stabilized.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Pulmicort Turbohaler

Evidence for Asthma: Long-term Maintenance Therapy

The research base for inhaled budesonide, the active ingredient in Pulmicort Turbohaler, primarily consists of Randomized Controlled Trials (RCTs) and associated meta-analyses that explored its role as a long-term control treatment. These trials were used in research exploring how symptoms change over time and applied in studies examining patient-reported experiences related to chronic asthma. Researchers examined outcomes related to functional imbalance, such as the objective measurement of lung function (like FEV1), and patient-reported outcomes describing perceived discomfort and the daily use of short-acting rescue inhalers.

Studies explored the effects over defined time intervals, monitoring subjects with conditions characterized by fluctuating or episodic manifestations of asthma. Studies monitored how lung function measurements evolved in the observed populations. Research also examined changes measured during the study period concerning the number of times subjects reported needing to use a rescue inhaler.

Evidence for Prophylactic Use and Exacerbation Reduction

Another major focus of the evidence base was on the medicine's role as a prophylactic (preventive) treatment against acute and disruptive episodes of asthma. Research examined studies conducted during periods of increased symptom activity, primarily through large-scale RCTs that tracked clinical events over a year. The studies monitored outcomes describing episodic or acute changes, focusing specifically on the annual rate of severe asthma exacerbations and the recording of subsequent treatment with oral corticosteroids or hospitalization.

Studies monitored patterns related to a recorded change in the number of severe exacerbations observed in the study populations. The volume and design of the available studies contributed to the regulatory classification of the evidence base.

Long-term Follow-up and Consistency of Reported Outcomes

Studies have explored the long-term consistency of reported outcomes and long-term outcomes beyond the initial evaluation periods (e.g., 52 weeks). This research provides context but not individual predictions, exploring how measurements of lung function evolved over multiple years of use. Long-term effects are not fully established for every functional outcome. Data for certain groups remain insufficient, meaning there is limited information for long-term outcomes in specific, smaller subgroups of patients.

Key Studies & References

  1. European Medicines Agency (EMA) Assessment of Paediatric Data: Pulmicort Turbuhaler Powder for Inhalation
  2. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children: a Cochrane Review
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Pulmicort Turbohaler (FAQ)


Q: What is the general approach described in official documents regarding a missed use of Pulmicort Turbohaler?

Official guidelines describe that if a dose is forgotten, the next step is to omit the missed dose entirely. The medication schedule is then continued by taking the next dose at the regularly scheduled time. The documentation specifies not to take a double dose to make up for the forgotten one.

Q: What information is available regarding the effect of Pulmicort Turbohaler on bone mineral density over time?

Official safety information for the corticosteroid drug class indicates that prolonged use, particularly when higher doses are utilized, may be associated with a decrease in bone mineral density (weakened bones). This potential systemic effect is described as a consideration for long-term therapy with any inhaled corticosteroid.

Q: What should be known about using Pulmicort Turbohaler alongside common pain relievers?

Official documents describe that inhaled corticosteroids may potentially increase the risk of gastrointestinal side effects, such as stomach ulcers, when used concurrently with certain non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. This is a general caution related to the corticosteroid drug class.

Q: Does Pulmicort Turbohaler have a known effect on sleep patterns?

Official product information indicates that, in rare instances, inhaled corticosteroids may cause sleep disturbances or disorders. These effects are uncommon and may also be accompanied by symptoms like anxiety or psychomotor hyperactivity, predominantly in the pediatric population.

Q: Can using Pulmicort Turbohaler lead to weight gain?

Weight gain has been documented as an uncommon side effect in some post-marketing reports. It may rarely be associated with systemic effects that include Cushingoid features, such as fat deposits around the trunk.

Q: Are there specific warnings or precautions noted for elderly patients using Pulmicort Turbohaler?

Regulatory guidelines describe that no routine dose adjustment is specified for elderly patients based on age alone. Eligibility for use is instead based on the specific respiratory condition and a review of any other existing health issues.

Q: Can I use a spacer device with the Pulmicort Turbohaler?

The Pulmicort Turbohaler is a Dry Powder Inhaler (DPI) intended for direct oral inhalation only. Official instructions specify that a spacer device is generally not used with this specific type of inhaler system.

Q: What are the ingredients of Pulmicort Turbohaler besides the active drug budesonide?

Based on regulatory data from certain regions, the Pulmicort Turbohaler is listed as a single-component powder containing only the active drug budesonide. This means it contains no nonmedicinal excipients (inactive ingredients).

Q: Does Pulmicort Turbohaler contain any ingredients that could trigger allergic reactions, such as lactose?

The Pulmicort Turbohaler formulation is specifically listed in certain product monographs as containing no nonmedicinal ingredients (excipients), meaning it is primarily just the active drug, budesonide. However, if a patient has a known allergy to any ingredient in the device or drug, regulatory documents caution against its use.

Q: What are the differences between Pulmicort Turbohaler and other products in the Pulmicort line, such as Pulmicort Respules?

The Pulmicort product line comes in different forms based on the patient's needs and age. Pulmicort Turbohaler is a dry powder inhaler (DPI) for use by children aged 6 and older, adolescents, and adults. In contrast, Pulmicort Respules is a liquid formulation intended for use with a nebulizer machine, typically prescribed for younger children.

Q: What are the signs that Pulmicort Turbohaler is functioning correctly after inhalation?

The Turbohaler device is designed to deliver a very finely milled powder in a precise dose. Patient instructions often describe that the fine powder means a user may not taste or feel the medicine after a correct, deep inhalation. This absence of sensation is not reported to indicate device failure.

Q: Is it possible to accidentally take too much of the dose from the Turbohaler device?

The Turbohaler device is engineered to load only a single, measured dose each time the grip is twisted and reset, which prevents accidental double-dosing. Patient instructions describe that if the device is accidentally dropped or breathed into after loading, the dose of medicine may be lost.

Advertisements

How should Pulmicort Turbohaler be stored and disposed of?

Storage and Disposal of Pulmicort Turbohaler

Pulmicort Turbohaler must be stored under specific environmental constraints to maintain the stability of the dry powder formulation. The product requires storage at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be kept in a dry place protected from dampness. The inhaler must not be refrigerated or frozen. After each use, the white cover must be firmly twisted back on. The device is considered empty and must be discarded when the red mark reaches the bottom of the dose indicator window, or when the expiration date is reached. The inhaler should be stored out of the sight and reach of young children. Disposal of any unused medication or the empty device must be done in accordance with local waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pulmicort Turbohaler found in:

A-Z Index: